文献速递瓣膜病与结构性心脏病

TAVR术后30天肾功能变化与1年结局:PARTNER 1研究

Association of Transcatheter Aortic Valve Replacement With 30-Day Renal Function and 1-Year Outcomes Among Patients Presenting With Compromised Baseline Renal Function: Experience From the PARTNER 1 Trial and Registry.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究基于PARTNER 1试验及注册研究,纳入821例基线eGFR≤60 mL/min且接受TAVR的重度主动脉瓣狭窄患者,按30天eGFR变化分为改善、恶化、无变化三组。结果显示基线肾功能不全常见,eGFR改善未改善1年结局,而eGFR恶化与死亡率增加相关。

要点

  • 基线eGFR≤60 mL/min者占72%,30天时42%改善、24%恶化、34%无变化。
  • 1年死亡率预测因素包括基线LVEF、基线eGFR及eGFR恶化(vs无变化)。

核心结论

  • 接受TAVR的患者中基线肾功能不全常见,eGFR改善未改善1年结局,而eGFR恶化与死亡率增加相关。

研究设计与样本

  • PARTNER 1试验及继续准入注册研究的亚组分析,纳入821例基线eGFR≤60 mL/min且接受TAVR并有基线与30天配对肾功能数据的患者,来自美国和加拿大25个中心。

主要发现

  • 821例中72%基线eGFR≤60 mL/min,30天时345例(42%)改善、196例(24%)恶化、280例(34%)无变化。
  • eGFR改善组与无变化组相比,30天至1年死亡率和重复住院无差异。

临床怎么用

  • 对于接受TAVR的基线肾功能不全患者,术后30天eGFR恶化与1年死亡率增加相关,需关注肾功能变化。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The frequency of baseline renal impairment among high-risk and inoperable patients with severe aortic stenosis undergoing a transcatheter aortic valve replacement (TAVR) and the effect of TAVR on subsequent renal function are, to our knowledge, unknown. OBJECTIVE: To determine the effect of TAVR among patients with baseline renal impairment. DESIGN, SETTING, AND PARTICIPANTS: This substudy of patients with baseline renal impairment (estimated glomerular filtration rate [eGFR] ≤ 60 mL/min) and paired baseline and 30-day measures of renal function undergoing TAVR in the PARTNER 1 trial and continued access registries was conducted in 25 centers in the United States and Canada. MAIN OUTCOMES AND MEASURES: Patients were categorized with improved eGFR (30-day follow-up eGFR≥10% higher than baseline pre-TAVR), worsened eGFR (≥10% lower), or no change in renal function (neither). Baseline characteristics, 30-day to 1-year all-cause mortality, and repeat hospitalization were compared. Multivariable models were constructed to identify predictors of 1-year mortality and of improvement/worsening in eGFR. RESULTS: Of the 821 participants, 401 (48.8%) were women and the mean (SD) age for participants with improved, unchanged, or worsening eGFR was 84.90 (6.91) years, 84.37 (7.13) years, and 85.39 (6.40) years, respectively. The eGFR was 60 mL/min or lower among 821 patients (72%), of whom 345 (42%) improved, 196 (24%) worsened, and 280 (34%) had no change at 30 days. There were no differences in baseline age, body mass index, diabetes, chronic obstructive pulmonary disease, coronary artery disease, peripheral arterial disease, hypertension, pulmonary hypertension, renal or liver disease, New York Heart Association III/IV symptoms, transaortic gradient, left ventricular ejection fraction, or procedural characteristics. The group with improved eGFR had more women, nonsmokers, and a lower cardiac index. Those with worsening eGFR had a higher median Society of Thoracic Surgeons score and left ventricle mass. From 30 days to 1 year, those with improved eGFR had no difference in mortality or repeat hospitalization. Those with worsening eGFR had increased mortality (25.5% vs 19.1%, P = .07) but no significant increases in repeat hospitalization or dialysis. Predictors of improved eGFR were being female (odds ratio [OR], 1.38; 95% CI, 1.03-1.85; P = .03) and nonsmoking status (OR, 1.49; 95% CI, 1.11-1.01; P = .01); predictors of worsening eGFR were baseline left ventricle mass (OR, 1.00; 95% CI, 1.00-1.01; P = .01), smoking (OR, 1.51; 95% CI, 1.06-2.14; P = .02), and age (OR, 1.03; 95% CI, 1.00-1.05; P = .05); and predictors of 1-year mortality were baseline left ventricular ejection fraction (OR, 0.98; 95% CI, 0.97-0.99; P = .003), baseline eGFR (OR, 0.98; 95% CI, 0.96-0.99; P < .001), and worsening eGFR vs no change in eGFR (OR, 1.51; 95% CI, 1.02-2.24; P = .04). CONCLUSIONS AND RELEVANCE: Baseline renal impairment was frequent among patients who underwent TAVR. While improved eGFR did not improve 1-year outcomes, worsening eGFR was associated with increased mortality. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00530894.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Beohar N, Doshi D, Thourani V, et al. Association of Transcatheter Aortic Valve Replacement With 30-Day Renal Function and 1-Year Outcomes Among Patients Presenting With Compromised Baseline Renal Function: Experience From the PARTNER 1 Trial and Registry. JAMA Cardiol. 2017. PMID: 28467527. doi:10.1001/jamacardio.2017.1220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。